Pharmacogenomics: the genomics of drug response.
Pharmacogenomics is defined as the study of the association between genetics and drug response. This is a rapidly expanding field with the hope that, within a few years, prospective genotyping will lead to patients being prescribed drugs which are both safer and more effective ('the right drug for the right patient', or personalized medicine). There are many existing examples in the literature of strong associations between genetic variation and drug response, and some of these even form the basis of accepted clinical tests. The molecular basis for some of these associations is described, and includes examples of variation in genes responsible for absorption and metabolism of the drug, and in target and disease genes. However, there are many issues surrounding the legal, regulatory and ethical framework to these studies that remain unanswered, and a huge amount of education both for the public and healthcare professionals will be needed before the results of this new medicine can be widely accepted.
March
R
R
Research & Development Genetics, AstraZeneca, Mereside, Macclesfield, Cheshire, UK. Ruth.March@astrazeneca.com
D004358:Drug Therapy; D064420:Drug-Related Side Effects and Adverse Reactions; D020869:Gene Expression Profiling; D016678:Genome; D006801:Humans; D020407:Internet; D004364:Pharmaceutical Preparations / Q000378:metabolism*; D010597:Pharmacogenetics; D011110:Polymorphism, Genetic
D004364:Pharmaceutical Preparations